The use of decongestants for the treatment of runny nose symptom in children: the clinical and pharmaceutical analysis of the pharmaceutical market of Ukraine

Authors

DOI:

https://doi.org/10.24959/cphj.20.1516

Keywords:

acute rhinosinusitis, acute respiratory viral infections, runny nose, decongestants for topical use in diseases of the nasal cavity, childhood

Abstract

The rational treatment of acute rhinosinusitis of infectious or allergic origin is an urgent task of both therapeutic and pediatric practice. This problem is of particular importance in connection with its prevalence in children, with a large list of drugs for the symptomatic treatment, the presence of significant side effects in active pharmaceutical ingredients, the peculiarities of the use of dosage forms, as well as a wide range of OTC drugs, including those approved for use in children.

Aim. To develop recommendations for introducing changes or additions to the peculiarities of using decongestants for topical use in diseases of the nasal cavity (sympathomimetics, corticosteroids, antihistamines, etc.) in children (under 15 years of age) in the Protocol of the Pharmacist “Symptomatic treatment of rhinitis”.

Materials and methods. To achieve the goal, the clinical and pharmaceutical analysis of decongestants for local use in diseases of the nasal cavity (sympathomimetics, corticosteroids, antihistamines, etc.), registered and marketed inUkraine was performed.

Results. As a result of the study it has been found that in February 2020 there are 146 decongestants for local use in diseases of the nasal cavity registered at the Ukrainian market. 87.7 % of the drugs are OTC and can be used by patients/patient representatives independently. 12.3 % of the drugs (18 items, mainly from the group of corticosteroids) are dispensed by prescription. The analysis of the composition of decongestants has been performed; it has been found that agents based on oxymetazoline (21.2 %) and xylometazoline and its combinations (39 %) prevail. When studying the prescribing information it has been found that 136 of 146 trade names can be used in the case of a cold in children under the age of15. In addition, depending on the age, the ranking of their active pharmaceutical ingredients (APIs) can be presented by the following sequence: sodium chloride (0.65 %), phenylephrine hydrochloride (0.125 %), oxymetazoline hydrochloride (0.01 %). Clinical and pharmacological evaluation of undesirable effects of APIs and the ways of their prevention have been performed.

Conclusions. The range and presence of undesirable effects of APIs of modern decongestants requires a cautious approach to responsible self-medication and a careful selection of the drug for the symptomatic treatment of acute rhinosinusitis in children. It is recommended to clarify the Protocol of the Pharmacist “Symptomatic treatment of rhinitis” on the possibility of using decongestants for topical use in diseases of the nasal cavity in children of different ages.

Author Biographies

V. V. Propisnova, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

S. V. Mіsiurova, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Clinical Pharmacology and Clinical Pharmacy

References

Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy : Hostryi rynosynusyt. (n.d.). Available at: https://dec.gov.ua/wp-content/uploads/images/dodatki/2016_85_GRS/2016_85_YKPMD_GRS.pdf.

Popovych, V.I.(2018). Ukrainskyi medychnyi chasopys, 2 (1). Available at: https://www.umj.com.ua/article/124534/suchasna-terapiya-gostrogo-rinosinusitu- 5-krokiv-profilaktiki-antibiotikorezistentnosti.

Popovych, V.I.(2014). Pediatriia, 1 (28), 35.

Beketova, H. V. (2016). Zdorove rebenka, 3 (71), 89–94.

Zupanets, I. A., Popovych, V. I., Zhulai, T. S., Volosovets, O. P., Shebeko, S. K., Kryvopustov, S. P., Sakharova, T. S., Bezuhla, N. P. (2019). Farmatsevtychna opika patsiientiv pry likuvanni hostroho rynosynusytu. Kharkiv: Zoloti storinky, 36.

Nakaz MOZ № 875 vid 11.10.2013 r. «Pro zatverdzhennia protokoliv provizora (farmatsevta) pry vidpusku bezretsepturnykh likarskykh zasobiv». (2013). ips.ligazakon.net. Available at: https://ips.ligazakon.net/document/view/ moz13716.

Nakaz MOZ Ukrainy № 876 vid 18.04.2019 r. «Pro zatverdzhennia Pereliku likarskykh zasobiv, dozvolenykh dlia zastosuvannia v Ukraini, yaki vidpuskaiutsia bez retseptiv z aptek ta yikh strukturnykh pidrozdiliv». (2019). zakon.rada.gov.ua. Available at: https://zakon.rada.gov.ua/laws/show/z0509-19.

Derzhavnyi reiestr likarskykh zasobiv. (n. d.). Available at: http://www.drlz.com.ua.

Kompendyum. ATS–klassyfykatsyia. (n. d.). Available at: https://compendium.com.ua/atc/.

Derzhavnyi formuliar likarskykh zasobiv Ukrainy. (n. d.). Available at: https://dec.gov.ua/materials/chinnij-vipusk-derzhavnogo-formulyara-likarskih-zasobiv/.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Nazo Bebi. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/36ED2A21850DCDB4C225825000700E34/$file/UA158080101_7A69.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Sanoryn. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/A57E780823EAFA69C22584B6003B9DFB/$file/UA24550402_CC88.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Fliks. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/3660ECE8370CC298C225842A00334E10/$file/UA134630101_C056.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho preparatu Tafen Nazal. (n. d.). Available at: http://drlz.com.ua/ibp/lz_www.nsf/id/3205B9AD0EE8FADCC225849E002BB848/$file/UA73860101_2E89.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho preparatu Hlensprei Aktyv. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/8C2B6AB07BCD4283C2258424002B2DCD/$file/UA145500101_6AB7.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho preparatu Polideksa z fenilefrynom. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/8D0A464300EF70B6C2258514003CFCAD/$file/UA28310101_DFBF.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Protarhol. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/6165DC0AB8013D6CC22584C80033C784/$file/UA150420101_90F3.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Izofra. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/7465FEFFEA5F6D34C22583F60025E8CA/$file/UA28300101_CD23.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Akvamaks. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/C5C85972637135E1C22582E300393B04/$file/UA128320101_1019.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Pinosol. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/71C236404817ADE8C22583F60025ECA0/$file/UA66060101_CCA6.mht.

Instruktsiia dlia medychnoho zastosuvannia likarskoho zasobu Pinovit. (n. d.). Available at: http://www.drlz.com.ua/ibp/lz_www.nsf/id/AB8F87DD6AD694BFC2258295003C5F81/$file/UA66060201_CB41.mht.

Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., … Alobid, I. (2020). European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology Journal, 20 (58 (Suppl S 29)), 1–464. doi: https://doi.org/10.4193/rhin20.600.

Downloads

Published

2020-09-03

Issue

Vol. 24 No. 3 (2020)

Section

Clinical Pharmacology and Pharmacotherapy

License

Copyright (c) 2020 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).